Patents Assigned to Daiichi Sankyo Company, Limited
-
Patent number: 11806339Abstract: The present invention provides a medicament comprising a compound represented by general formula (1) which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor in combination, and a method for treating cancer using this combination. The present invention provides an excellent medicament and method for treating cancer which is highly effective for inhibiting resistance to an EGFR tyrosine kinase inhibitor in cancer treatment, and causes less adverse reactions such as weight loss.Type: GrantFiled: May 2, 2022Date of Patent: November 7, 2023Assignee: Daiichi Sankyo Company, LimitedInventor: Takeshi Jimbo
-
Publication number: 20230348522Abstract: The present invention provides a crystalline 2,4-bridged common intermediate useful for producing a plurality of ENA monomers, a method for stereoselectively producing the intermediate, and a method for efficiently producing ENA monomers using the intermediate.Type: ApplicationFiled: October 16, 2020Publication date: November 2, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Michida, Kazutoshi Ukai, Yuzo Abe, Moe Matsumoto, Makoto Yamaoka, Kei Kurahashi
-
Publication number: 20230348616Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.Type: ApplicationFiled: March 29, 2021Publication date: November 2, 2023Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho KOZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
-
Publication number: 20230340118Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.Type: ApplicationFiled: May 10, 2023Publication date: October 26, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Keisuke FUKUCHI, Kayoko NANAI, Masato AMANO, Kozo YONEDA, Yusuke TOTOKI, Shoji YAMAMOTO
-
Patent number: 11795236Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting positionType: GrantFiled: September 13, 2018Date of Patent: October 24, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Publication number: 20230330243Abstract: A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond.Type: ApplicationFiled: June 23, 2021Publication date: October 19, 2023Applicants: Daiichi Sankyo Company, Limited, AstraZeneca UK LimitedInventors: Jerome Thomas METTETAL, II, Stephen Thomas DURANT, Azadeh Cheraghchi Bashi ASTANEH, Alan Yin Kai LAU, Yann WALLEZ
-
Publication number: 20230331700Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: A: e.g., Benzene, E: e.g., —CH2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R1, R2, R3: e.g., a halogen atom, R4: e.g., a C1-C6 alkyl group, R5: e.g., a hydrogen atom, R6a, R6b, R6c, R6d: e.g., a hydrogen atom, R7: e.g., a hydrogen atom, R8: e.g., a hydrogen atom, n1, n2, n3: e.g., 1.Type: ApplicationFiled: November 21, 2022Publication date: October 19, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Toru Taniguchi, Osamu Iwamoto, Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Nobuya Kurikawa, Seiko Nagata, Kaori Ito, Eriko Kioi
-
Publication number: 20230330248Abstract: [Problem] It is desired to develop an antibody-drug conjugate capable of being systemically administered and delivering a STING agonist specifically to a target cells or organ (for example, a tumor lesion), and a therapeutic agent and/or therapeutic method using the antibody-drug conjugate for diseases related to STING agonist activity, for example, diseases (for example, cancers) to which immunostimulation therapy can be applied. [Solution] The present invention provides a novel antibody-CDN derivative conjugate which can be systemically administered and exhibits an antitumor effect against an antigen-expressing tumor.Type: ApplicationFiled: March 5, 2021Publication date: October 19, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Masayuki ISHIZAKI, Osamu SUZUKI, Mariko KYUTOKU, Hiroshi YUKIURA, Kyoko HARA, Masataka CHIHARA, Takafumi OTSUKA, Teiji WADA
-
Publication number: 20230293714Abstract: A pharmaceutical composition, wherein an anti-HER2 antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents a connecting position to an anti-HER2 antibody) is conjugated to the anti-HER2 antibody via a thioether bond, and a HER dimerization inhibitor are administered in combination, and/or a method of treatment, wherein the anti-HER2 antibody-drug conjugate and a HER dimerization inhibitor are administrated in combination to a subject.Type: ApplicationFiled: July 19, 2021Publication date: September 21, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventor: Yasuki KAMAI
-
Publication number: 20230287119Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.Type: ApplicationFiled: April 3, 2023Publication date: September 14, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Tohru TAKAHASHI, Chigusa YOSHIMURA, Shiho KOZUMA, Kensuke NAKAMURA, Chikako SUZUKI, Junya ICHIKAWA
-
Publication number: 20230287121Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.Type: ApplicationFiled: May 16, 2023Publication date: September 14, 2023Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho OKZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
-
Publication number: 20230277679Abstract: A method for producing an antibody-drug conjugate composition, comprising: (i) a step of reacting an antibody with a reducing agent to obtain an antibody having thiol groups; then (ii) a step of reacting drug-linker intermediates with the antibody having thiol groups obtained in the step (i), wherein the step (i) is carried out until the composition ratio of the antibody having four heavy-light interchain thiols and the composition ratio of the antibody having four heavy-heavy interchain thiols reach a steady value.Type: ApplicationFiled: July 16, 2021Publication date: September 7, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hitoshi SATO, Yuka SASORI, Daisuke FUKATSU
-
Publication number: 20230270870Abstract: The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-trophoblast cell surface antigen 2 (TROP2) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor.Type: ApplicationFiled: May 28, 2020Publication date: August 31, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Yutaka NOGUCHI, Tomonari YAMASHITA, Daisuke OKAJIMA, Takuma IGUCHI, Satoru YASUDA, Jonathan GREENBERG
-
Publication number: 20230265431Abstract: Provided is a short-chain guide RNA that is able to induce site-specific editing even when only a small number of nucleotides is attached to the target recognition site. The guide RNA includes a first oligonucleotide that identifies the target RNA, and a second oligonucleotide that links to the 3? end of the first oligonucleotide. The first oligonucleotide contains: a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 15 to 30 residues that links to the 5? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA; and an oligonucleotide of 3 or 4 residues that links to the 3? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA. The second oligonucleotide contains 2 to 24 nucleotide residues, and induces site-specific editing of the target RNA.Type: ApplicationFiled: March 22, 2023Publication date: August 24, 2023Applicants: FUKUOKA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventor: Masatora FUKUDA
-
Publication number: 20230257767Abstract: The present invention provides an approach to enhancing the production of a foreign protein serving as a protein-based pharmaceutical product in host cells such as cultured cells derived from a mammal. The present invention provides transformed cells having a novel Hspa5 gene promoter, and a method for secreting and producing a foreign protein at high levels using the transformed host cells.Type: ApplicationFiled: January 12, 2023Publication date: August 17, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Kenji Masuda, Koichi Nonaka, Hiroki Tanemura
-
Publication number: 20230257368Abstract: An object of the present invention is to provide an industrially useful and novel process for producing a 1,3-benzodioxole derivative, with high yield and few impurities, including a novel chlorination reaction of a benzene ring. In the novel process for producing a 1,3-benzodioxole derivative, it has been found that an industrially useful and novel chlorination reaction of a benzene ring is conducted by using sulfuryl chloride with high yield and few impurities. Based on the finding, the invention has been accomplished.Type: ApplicationFiled: July 7, 2021Publication date: August 17, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsuyoshi UEDA, Yuji KAIYA, Takahisa UCHIDA, Makoto IMAI
-
Publication number: 20230226205Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.Type: ApplicationFiled: July 26, 2022Publication date: July 20, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Atsuko SAITO, Tsuyoshi HIRATA, Kensuke NAKAMURA
-
Publication number: 20230212306Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.Type: ApplicationFiled: December 27, 2022Publication date: July 6, 2023Applicants: Daiichi Sankyo Company, Limited, The University of TokyoInventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
-
Publication number: 20230203132Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.Type: ApplicationFiled: November 21, 2022Publication date: June 29, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Hidenori Yano, Daisuke Nishimiya, Ryuji Hashimoto, Yoichi Niitsu
-
Patent number: 11667642Abstract: Provided is a novel and industrially useful method for producing a 3,6-disubstituted imidazo[1,2-b]pyridazine derivative. The present invention provides a method for producing a 3,6-disubstituted imidazo[1,2-b]pyridazine derivative, which uses 6-fluoroimidazo[1,2-b]pyridazine as a starting material, while using an aromatic substitution reaction that utilizes C—H activation by means of palladium.Type: GrantFiled: February 1, 2021Date of Patent: June 6, 2023Assignee: Daiichi Sankyo Company, LimitedInventors: Ryoji Koike, Yoshifumi Hachisu, Takafumi Kitawaki, Shohei Shiraishi